JP2002535334A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535334A5 JP2002535334A5 JP2000594813A JP2000594813A JP2002535334A5 JP 2002535334 A5 JP2002535334 A5 JP 2002535334A5 JP 2000594813 A JP2000594813 A JP 2000594813A JP 2000594813 A JP2000594813 A JP 2000594813A JP 2002535334 A5 JP2002535334 A5 JP 2002535334A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- furano
- tetrahydropyridine
- disorder
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000033808 peripheral neuropathy Diseases 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- -1 3-nitrophenyl Chemical group 0.000 description 1
- 0 Cc1c(*)c(CN(*)CC2)c2[o]1 Chemical compound Cc1c(*)c(CN(*)CC2)c2[o]1 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK199900061 | 1999-01-19 | ||
| DKPA199900061 | 1999-01-19 | ||
| PCT/DK2000/000012 WO2000043397A1 (en) | 1999-01-19 | 2000-01-13 | Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002535334A JP2002535334A (ja) | 2002-10-22 |
| JP2002535334A5 true JP2002535334A5 (enExample) | 2007-02-22 |
Family
ID=8089290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000594813A Pending JP2002535334A (ja) | 1999-01-19 | 2000-01-13 | 縮合ヘテロ環状化合物及びこれを神経変性疾患の治療に使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6576641B2 (enExample) |
| EP (1) | EP1147113B1 (enExample) |
| JP (1) | JP2002535334A (enExample) |
| CN (1) | CN1147490C (enExample) |
| AT (1) | ATE328887T1 (enExample) |
| AU (1) | AU776276B2 (enExample) |
| CA (1) | CA2353903A1 (enExample) |
| DE (1) | DE60028538T2 (enExample) |
| NZ (1) | NZ512289A (enExample) |
| WO (1) | WO2000043397A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311386T1 (de) * | 2001-09-24 | 2005-12-15 | Bayer Pharmaceuticals Corp | Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit |
| KR100553398B1 (ko) | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| KR102074089B1 (ko) | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| JP7187437B2 (ja) | 2016-07-29 | 2022-12-12 | サノビオン ファーマシューティカルズ インク | 化合物および組成物ならびにそれらの使用 |
| EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| CN112135827B (zh) | 2018-02-16 | 2024-01-12 | 赛诺维信制药公司 | 盐、晶型及其制备方法 |
| KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
| WO2021211489A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| PE20242113A1 (es) | 2021-10-14 | 2024-10-28 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2395028A2 (fr) * | 1977-06-22 | 1979-01-19 | Centre Etd Ind Pharma | Derives pyridiniques, leur preparation et leurs application therapeutique |
| FR2566775B1 (fr) | 1984-06-27 | 1986-10-31 | Synthelabo | Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique |
| FR2570701B1 (fr) * | 1984-09-27 | 1987-05-22 | Synthelabo | Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique |
| FR2635977B1 (fr) * | 1988-09-07 | 1992-05-15 | Synthelabo | Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l'obesite |
| GB8921465D0 (en) * | 1989-09-22 | 1989-11-08 | Fujisawa Pharmaceutical Co | Bicyclic amine compound and a process for the preparation thereof |
| FR2652579B1 (fr) * | 1989-10-02 | 1992-01-24 | Sanofi Sa | Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique. |
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| CA2200469A1 (en) * | 1994-10-11 | 1996-04-18 | Takeda Chemical Industries, Ltd. | Condensed compounds, their production and use |
| CN1250528C (zh) * | 1995-09-11 | 2006-04-12 | 阿温蒂斯药物公司 | 环状硝酮和含有它们的药用组合物 |
-
2000
- 2000-01-13 EP EP00900497A patent/EP1147113B1/en not_active Expired - Lifetime
- 2000-01-13 CN CNB008027080A patent/CN1147490C/zh not_active Expired - Fee Related
- 2000-01-13 DE DE60028538T patent/DE60028538T2/de not_active Expired - Lifetime
- 2000-01-13 CA CA002353903A patent/CA2353903A1/en not_active Abandoned
- 2000-01-13 NZ NZ512289A patent/NZ512289A/xx not_active IP Right Cessation
- 2000-01-13 JP JP2000594813A patent/JP2002535334A/ja active Pending
- 2000-01-13 AU AU30333/00A patent/AU776276B2/en not_active Ceased
- 2000-01-13 WO PCT/DK2000/000012 patent/WO2000043397A1/en not_active Ceased
- 2000-01-13 AT AT00900497T patent/ATE328887T1/de not_active IP Right Cessation
-
2001
- 2001-06-07 US US09/875,019 patent/US6576641B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102149321B1 (ko) | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 | |
| WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
| EP3606525B1 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| JP2002535334A5 (enExample) | ||
| JP6750900B2 (ja) | 選択された抗コリン作用性双性イオンの使用 | |
| DE69935670T2 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| JP2003528136A (ja) | 運動障害の治療 | |
| JP2019524897A5 (enExample) | ||
| JPWO2002034264A1 (ja) | 筋萎縮性側索硬化症（ａｌｓ）治療剤 | |
| WO2008003511A1 (en) | Use of aminothiazole derivative compounds, pharmaceutical compositions thereof, in the treatment of diseases characterized by abnormal repression of gene transcription, particularly huntington's disease | |
| JP2021527090A (ja) | 老化関連神経変性の進行および／または発症を治療および／または予防するための方法および組成物 | |
| CN114040757A (zh) | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 | |
| TR201809537T4 (tr) | Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. | |
| JPH11515012A (ja) | 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用 | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| EA036347B1 (ru) | Комбинация чистых антагонистов 5-ht6 рецепторов с ингибиторами ацетилхолинэстеразы | |
| JPH05500502A (ja) | 眼の発達の治療及び制御 | |
| MX2007007472A (es) | Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c. | |
| JP6830895B2 (ja) | ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン | |
| JP2022514659A (ja) | ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン | |
| JP2003523385A (ja) | 神経変性疾患の治療法 | |
| JP2006513207A5 (ja) | 行動障害治療剤 | |
| US20040220221A1 (en) | Treatment of degenerative diseases | |
| JP2013517301A (ja) | 式ｉで示される少なくとも１種のイソキノリン化合物の使用、神経変性疾患を治療または予防するための医薬組成物、および、神経変性疾患を治療または予防する方法 | |
| TWI654976B (zh) | 選定的抗膽素激導性兩性離子之用途 |